RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 133 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.76 and the average weighting 2.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,951,899 | +330.9% | 3,523,124 | +320.7% | 0.02% | +340.0% |
| Q2 2023 | $6,255,378 | +86.8% | 837,400 | +66.8% | 0.01% | +150.0% |
| Q1 2023 | $3,348,187 | -4.5% | 501,977 | +10.4% | 0.00% | -33.3% |
| Q4 2022 | $3,504,365 | -32.9% | 454,522 | -7.4% | 0.00% | -25.0% |
| Q3 2022 | $5,221,000 | +60.4% | 490,740 | +22.7% | 0.00% | +33.3% |
| Q2 2022 | $3,255,000 | -48.5% | 399,901 | +8.4% | 0.00% | -25.0% |
| Q4 2021 | $6,321,000 | -32.9% | 368,994 | -9.8% | 0.00% | -33.3% |
| Q3 2021 | $9,416,000 | +20.8% | 409,194 | +91.6% | 0.01% | +20.0% |
| Q2 2021 | $7,797,000 | – | 213,608 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Data Collective IV GP, LLC | 5,941,120 | $45,806,035 | 48.11% |
| Kinnevik AB (publ) | 7,653,061 | $59,005,100 | 33.28% |
| MV Management XI, L.L.C. | 1,971,908 | $15,203,411 | 26.45% |
| MIC Capital Management UK LLP | 8,451,758 | $65,163,057 | 12.86% |
| ArchPoint Investors | 1,114,626 | $8,593,766 | 4.07% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $11,636,348 | 1.44% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,710,339 | $20,896,714 | 0.80% |
| Duquesne Family Office | 1,385,950 | $10,685,675 | 0.53% |
| ALLEN OPERATIONS LLC | 217,657 | $1,678,135 | 0.45% |
| Artal Group S.A. | 960,204 | $7,403 | 0.41% |